{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is CEL-SCI Corp. technically bullish or bearish?
As of June 20, 2025, CEL-SCI Corp. is in a bearish trend with moderate strength, indicated by bearish daily moving averages, KST, and OBV, despite a mildly bullish MACD, and has underperformed the S&P 500, reinforcing the overall bearish sentiment.
Who are in the management team of CEL-SCI Corp.?
As of March 2022, the management team of CEL-SCI Corp. includes CEO Geert Kersten, along with independent directors Bruno Baillavoine, Robert Watson, and Peter Young.
What does CEL-SCI Corp. do?
CEL-SCI Corporation focuses on researching and developing cancer treatments and other diseases by harnessing the immune system, operating as a micro-cap company in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported a net profit loss of $7 million and has a market cap of $11.91 million.
How big is CEL-SCI Corp.?
As of Jun 18, CEL-SCI Corp. has a market capitalization of 11.91 million, with net sales of 0.00 million and a net profit of -26.61 million over the latest four quarters. As of Sep 24, the company reports shareholder's funds of 12.87 million and total assets of 26.99 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
